Quidel nabs BARDA funding to develop test for respiratory viruses

Quidel (NASDAQ:QDEL) secures the Biomedical Advanced Research and Development Authority (“BARDA”) funding of $635,000 to support the development of a point-of-care diagnostic assay that potentially tests for four respiratory viruses: SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV). The respiratory virus panel would be developed to run on Quidel’s Sofia 2 flagship instrument.

The funding will run through April 2021 with he goal of achieving an FDA Emergency Use Authorization for the test.

https://seekingalpha.com/news/3582542-quidel-nabs-barda-funding-to-develop-test-for-respiratory-viruses